PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 虽然有许多治疗淋巴瘤、骨髓瘤和相关癌症的方法，但大多数患者并未治愈。这项研究的总体目的是改进淋巴瘤、骨髓瘤和相关癌症的治疗。 Bortezomib是一种被批准用于治疗骨髓瘤的新药。 实验室研究表明，Bortezomib可能有助于与研究药物Flaopiridol联合使用，以对抗骨髓瘤。这项研究将有助于确定这两种药物联合使用的合适剂量。这项研究将招募大约20名受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although there are many treatments for lymphomas, myelomas, and related cancers, most patients are not cured. The general purpose of this study is to improve the treatment of lymphomas, myeloma, and related cancers. Bortezomib is a new agent approved for the treatment of myeloma. Laboratory studies suggest that Bortezomib might be helpful in combating myelomas in combination with Flavopiridol (an investigational drug). This study will help identify the appropriate doses for the combination of the two drugs. This study will recruit approx 20 subjects.